Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression

CNS Spectrums

Volumn 17, Issue 3, 2012, Pages 107-120

  Lum, Christopher T ^a   Stahl, Stephen M ^b  

^a Arbor Scientia   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dietary interaction; Drug interaction; Hypertension; Reversible monoamine oxidase inhibitor; Serotonin syndrome; Treatment resistant depression

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CLOMIPRAMINE; CX 157; CYCLOBENZAPRINE; DECONGESTIVE AGENT; DOPAMINE; EPHEDRINE; FLUOXETINE PLUS OLANZAPINE; METHADONE; MONOAMINE OXIDASE A INHIBITOR; NORADRENALIN; OPIATE; OXCARBAZEPINE; OXYCODONE; PETHIDINE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; QUETIAPINE; REVERSIBLE MONOAMINE OXIDASE A INHIBITOR; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL PRACTICE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FOOD DRUG INTERACTION; HEALTH CARE COST; HUMAN; HYPERTENSION; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NEUROTRANSMISSION; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROTONIN SYNDROME; SIGNAL TRANSDUCTION; SYNAPSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; VAGUS NERVE STIMULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DIETARY SUPPLEMENTS; ENZYME INHIBITORS; HUMANS; MONOAMINE OXIDASE; NEUROTRANSMITTER AGENTS; SYNAPSES;

EID: 84869205664     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852912000594     Document Type: Article

References (37)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095-3105.
2. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64(12): 1465-1475.
3. Ioannidis JP. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med. 2008; 3: 14.
4. Golden SH, Williams JE, Ford DE, et al. Depressive symptoms and the risk of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2004; 27(2): 429-435.
5. Jonas BS, Franks P, Ingram DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-Up Study. Arch Fam Med. 1997; 6(1): 43-49.
6. Larson SL, Owens PL, Ford D, Eaton W. Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke. 2001; 32(9): 1979-1983.
7. Nelson JC. The STAR*D study: a four-course meal that leaves us wanting more. Am J Psychiatry. 2006; 163(11): 1864-1866.
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11): 1905-1917.
9. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002; 63(11): 963-971.
10. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010; 24(2): 131-161.
11. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. fully rev. expanded ed. Cambridge, UK: Cambridge University Press; 2008.
12. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006; 63(11): 1209-1216.
13. Meyer JH, Wilson AA, Sagrati S, et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry. 2009; 66(12): 1304-1312.
14. Johnson S, Stockmeier CA, Meyer JH, et al. The reduction of r1, a novel repressor protein for monoamine oxidase a, in major depressive disorder. Neuropsychopharmacology. 2011; 36(10): 2139-2148.
15. Atchley DW. Reevaluation of tranylcypromine sulfate. JAMA. 1964; 189: 763-764.
16. Grady M, Stahl SM. Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectr. 2012; 17: 2-10.
17. Billett EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology. 2004; 25(1-2): 139-148.
18. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999; 20(3): 226-247.
19. Bieck PR, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl. 1989; 28: 21-31.
20. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010; 77(12): 859-882.
21. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008; 13(10): 855-870.
22. Elis J, Laurence DR, Mattie H, Prichard BN. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J. 1967; 2(5544): 75-78.
23. Boakes AJ, Laurence DR, Teoh PC, et al. Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J. 1973; 1(5849): 311-315.
24. Horwitz D, Goldberg LI, Sjoerdsma A. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J Lab Clin Med. 1960; 56: 747-753.
25. Yagiela JA, Duffin SR, Hunt LM. Drug interactions and vasoconstrictors used in local anesthetic solutions. Oral Surg Oral Med Oral Pathol. 1985; 59(6): 565-571.
26. Wells DG, Bjorksten AR. Monoamine oxidase inhibitors revisited. Can J Anaesth. 1989; 36(1): 64-74.
27. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008; 7(5): 587-596.
28. Hilton SE, Maradit H, Moller HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci. 1997; 247(3): 113-119.
29. Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide. Antidepressants. 4th ed. Cambridge, UK: Cambridge University Press; 2011.
30. Raymond CB, Morgan SG, Caetano PA. Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatr Serv. 2007; 58(1): 79-84.
31. Karkare SU, Bhattacharjee S, Kamble P, Aparasu R. Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States. Am J Geriatr Pharmacother. 2011; 9(2): 109-119.
32. Shulman KI, Fischer HD, Herrmann N, et al. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry. 2009; 70(12): 1681-1686.
33. Coupland C, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011; 15(28): 1-202.
34. Fowler JS, Logan J, Azzaro AJ, et al. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010; 35(3): 623-631.
35. VanDenBerg CM, Blob LF, Kemper EM, Azzaro AJ. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003; 43(6): 604-609.
36. Burch D, Asgharnejad M, Gerson W. Lack of tyramine pressor response effect with oral CX157, a reversible MAOI. Paper presented at: American College of Neuropsychopharmacology, 50th annual meeting; December 4-8, 2011; Waikoloa Beach, HI.
37. Azzaro AJ, Vandenberg CM, Blob LF, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol. 2006; 46(8): 933-944.